Company intelligence / Profile preview

LONGU

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Longu is a synthetic biology company focused on the green manufacturing of high-value natural products and longevity-related compounds. The company utilizes metabolic engineering and advanced fermentation technologies to produce ingredients such as Nicotinamide Mononucleotide (NMN), Pyrroloquinoline Quinone (PQQ), and various ginsenosides. By replacing traditional chemical synthesis and extraction methods, Longu aims to provide sustainable and high-purity solutions for the healthcare, nutraceutical, and pharmaceutical industries. The company's platform is designed to accelerate the development of bioactive molecules that target aging and metabolic health.

Therapeutic areas: NeurologyOtherMetabolic Disorders
Modalities: Small moleculeNatural products
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on LONGU.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LONGU.

Explore the full profile